rituximab induction is a predictive biomarker in post-transplant lymphoproliferative disorder
Published 8 years ago • 865 plays • Length 4:16Download video MP4
Download video MP3
Similar videos
-
4:47
epstein-barr virus associated post-transplant lymphoproliferative disorder (ebv ptld)
-
5:11
posttransplant lymphoproliferative disorders - causes, symptoms, diagnosis, treatment, pathology
-
1:58
clinical outcomes of patients with ebv-ptld who fail rituximab following hsct
-
10:47
long-term outcomes of subjects with ebv driven ptld following solid organ or allogeneic hct trea...
-
53:56
association of antiviral prophylaxis and rituximab use with ptlds
-
1:56
strategies for the management of ebv-ptld
-
0:44
post-transplant lymphoproliferative disorder and the role of acyclovir in treatment
-
1:18
dr. prockop discusses tabelecleucel in post-transplant ebv lymphomas
-
2:41
cytotoxic t lymphocyte cell therapy directed against ebv ptld in the central nervous system
-
2:26
advances in ebv-ptld
-
0:43
post-transplant lymphoproliferative disorder (medical condition)
-
4:18:45
post-transplant lymphoproliferative disease externally-led patient-focused drug development meeting
-
1:24
ptld
-
2:24
the treatment and management of ptld
-
8:07
cystic fibrosis podcast 262: dealing with post-transplant ptld
-
34:02
christopher blosser, md - post-transplant lymphoproliferative disorders for nephrologists
-
3:16
tabelecleucel in the treatment of ebv ptld
-
48:24
dr eve crane - ebv-related lymphoproliferative disorders
-
1:28:45
post-transplant lymphoproliferativeddisorder (ptld)